TempraMed’s Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings model

Vancouver, British Columbia–(Newsfile Corp. – March 11, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company“), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the use of VIVI Cap for passive thermal protection of insulin during summer travel.

The paper, titled “Passive Thermal Protection of In-Use Insulin During Summer Travel: Device Description and Single-Patient Case Report with a Simple Cost Perspective,” was authored by TempraMed’s Medical Director, Prof. Andreas Pfützner, and colleagues and published in the Journal of Clinical & Medical Case Reports (February 2026).

The publication describes the use of VIVI Cap by a patient with type 1 diabetes during sustained high ambient temperatures (35-38°C) while traveling in Greece. Compared to a prior month without thermal protection, the patient demonstrated:

• Improved time-in-range (86% vs. 82%)
• Reduced time above 250 mg/dL (3% vs. 5%)
• Stable mealtime insulin requirements despite extreme heat
• No emergency department or urgent care visits

Importantly, the report emphasizes not only glycemic stability but also reduced anxiety and increased patient confidence regarding insulin effectiveness in hot climates, factors that directly influence healthcare utilization and medication wastage.

Scientific Evidence Supporting Economic Validation

The publication explicitly references TempraMed’s independently validated payer return-on-investment (ROI) model, noting that the primary economic value of thermal protection lies not in minor dose differences, but in:

• Prevention of medication wastage due to suspected temperature excursions
• Avoidance of heat-related glycemic deterioration
• Reduction in emergency events such as severe hyperglycemia and diabetic ketoacidosis (DKA)
• Lower anxiety-driven healthcare utilization

These are the same core drivers underlying TempraMed’s payer savings model, which recently received third-party validation for “Savings & Metrics” by the Validation Institute through January 2027.

While the published case represents a single-patient observation, the authors conclude that the clinical findings are consistent with the mechanistic rationale of VIVI Cap’s vacuum insulation and phase-change thermal buffering technology and support further prospective studies incorporating payer-relevant endpoints such as resource utilization and medication discard rates.

Strategic Significance

Management views the publication as an important bridge between:

1. Clinical plausibility: peer-reviewed evidence demonstrating preserved insulin stability and improved patient confidence in extreme conditions, and

2. Health-economic validation: independent confirmation that the payer ROI model is methodologically credible and aligned with real-world savings pathways.

“This publication provides scientific context to the economic case we have already validated,” said Ron Nagar, CEO of TempraMed. “It highlights how thermal protection can translate into clinical stability and patient confidence in high-risk environments-exactly the drivers incorporated into our validated payer ROI model. Together, clinical rationale and economic validation significantly strengthen our reimbursement discussions.”

Reimbursement and Market Impact

As TempraMed continues assessing pilot programs and coverage decisions with various payers, the combination of:

• Published scientific rationale,
• Real-world use case illustration, and
• Independently validated economic modeling

further supports the Company’s strategy to position VIVI Cap as a reimbursable, cost-saving standard in diabetes management and other temperature-sensitive therapies.

Management believes that continued publication, data generation, and payer engagement represent key catalysts in expanding coverage, accelerating adoption, and driving scalable revenue growth.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, space-grade thermal insulation devices that work 24/7 without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. Headquartered in Israel with operations in North America, Europe, and Asia, TempraMed is advancing the future of medication protection and adherence.

Investors interested learning more about TempraMed are encouraged to contact the Company at:

Cautionary Statements

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.

Cautionary Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “will,” “should,” “strategy,” “future,” “potential,” and similar expressions, or statements about events or conditions that may occur in the future.

Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s ability to leverage published clinical evidence and its independently validated payer ROI model to advance reimbursement discussions with payers; the anticipated impact of clinical publications and health-economic validation on payer engagement, coverage decisions, and pilot programs; the Company’s strategy to position VIVI Cap as a reimbursable, cost-saving standard in diabetes management and other temperature-sensitive therapies; the expectation that continued publication, data generation, and payer engagement will expand coverage, accelerate adoption, and drive scalable revenue growth; and the Company’s plans to pursue further prospective studies incorporating payer-relevant endpoints. Forward-looking statements are based on the opinions, expectations, and assumptions of management as of the date of this press release, including but not limited to: that published clinical evidence will be received favorably by payers and support reimbursement discussions; that the Company’s independently validated payer ROI model will remain current and credible for use in coverage negotiations; that the Company will have sufficient financial resources to pursue its reimbursement, commercialization, and clinical publication strategies; that suitable payer partners will engage with the Company on acceptable terms; and that market conditions will support demand for thermal protection products among patients, providers, and payers. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied, including but not limited to: the inherent limitations of single-patient case reports and early-stage clinical evidence; the risk that payers may not accept the Company’s ROI model or published evidence as sufficient basis for coverage or reimbursement; the Company’s ability to secure additional financing; changes in regulatory requirements or government policy; the ability to identify and secure commercialization partners; competitive developments in temperature-controlled medication storage and smart refrigeration technologies; general economic, market, and business conditions; and other risks described in the Company’s public filings available on SEDAR+ at www.sedarplus.ca.

The forward-looking statements contained in this press release are made as of the date hereof. Except as required by applicable securities laws, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288052